• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • China clinical trials for new drug registrations report for 2021 is published

China clinical trials for new drug registrations report for 2021 is published

china clinical trials for new drug
Wednesday, 13 July 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

China clinical trials for new drug registrations report for 2021 is published

China clinical trials for new drug registrations report for 2021 was released by the Center for Drug Evaluation (CDE) on June 7, 2022.

The report shows that the total annual registration volume of the new drug clinical trials (including innovative drugs and modified new drugs) in 2021 exceeded 3,000 for the first time with a total of 3,358 items. This represents a 29.1% increase compared with the total annual registration in 2020. Among them, the number of new drug clinical trials was 2,033, an increase of 38.0% over 2020.

Highlights

Registrations by drug type: over 70% were chemical drugs

In 2021, China’s drug clinical trials were still dominated by chemical drugs, accounting for 70.8%. This was followed by biological products at 26.7%. The least was Chinese medicine, only 2.4%. Compared with the data of the past three years, the proportion of clinical trials of various drugs is similar, but the proportion of biological products is increasing year on year, and the proportion of chemical drugs and traditional Chinese medicines is decreasing year on year.

Figure 1 – Changes in the overall proportion of each drug type (2019-2021)

New drug registrations by type of trial: Clinical trials (60.5%) vs bioequivalence trials (39.5%)

There were 2033 new drug clinical trials (60.5%) and 1325 bioequivalence trials (BE trials) (39.5%) registered in 2021. Compared with the data of the past three years, the proportion of clinical trials of new drugs has increased year on year, while the proportion of BE trials has decreased.

Figure 2 – Change in the proportion of new drug clinical trials by type of trial (2019-2021)

Drugs with most number of China registered clinical trials

Among the 2033 new drug clinical trials registered in 2021, the following table shows a variety of different chemical drugs with the most number of clinical trials registered, adding up to a total of 68 registered clinical trials (see Figure 3).

Figure 3 – Most number of China registered clinical trials for chemical drug products in 2021

The following table shows a variety of different biological products with the most number of clinical trials registered, adding up to a total of 104 registered clinical trials (see Figure 4).

Figure 4 – Most number of China registered clinical trials for biological products in 2021

Indications of the top 10 targeted drugs

The top 10 targets of registered clinical trials in 2021 can be seen in the graphic below. They are principally anti-tumor drugs (see Figure 5).

Figure 5 – Number of China clinical trials according to top 10 targets in 2021

Phase I – IV clinical trials for the top 10 targeted drugs

Among the top 10 targets, phase III clinical trials account for the largest proportion of PD-1 and PD-L1 targets. It is expected that the competition for PD-1 and PD-L1 targeted drugs will be more intense in the future.

Phase II clinical proportion of HER2 and EGFR targets is also relatively large.

Phase I clinical trials accounted for more than 40% of drug clinical trials in VEGFR, GLP-1/GLP-1R, JAK1 and CD3 (see Figure 6).

Figure 6 – Number of Phase I – IV clinical trials in China for the top 10 targets in 2021

Summary

Overall, at present, new drug research and development in China mainly revolves around the field of tumors, and most of them are in the early stage, mainly in Phase I clinical trials. The targets of new drugs are relatively concentrated with competition in PD-1/PD-L1 becoming red-hot.

If you are interested in conducting a China clinical trial for a new drug registration, please contact Cisema. We are experienced in establishing clinical trial protocols which conform to NMPA requirements and running local clinical trials in China for pharmaceuticals and medical devices alike.

By Yu. If you would like to learn more about the Annual Report on the Progress of Clinical Trials of New Drug Registration or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

china class I medical device filing
China class I medical device filing clarification
SAMR implements Administrative Measures for Product Quality Spot Inspections and Consumer Goods Recall Management for 2020
China Technical Guidelines Round Up for Medical Devices – November 2021

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP